Home
/
Xilio Therapeutics, Inc.
/
Financials
/
Quarterly
Xilio Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Xilio Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$19.07M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$8.08M
Aug 14, 2025
Q1
2025
Mar 31, 2025
$2.93M
May 8, 2025
Q3
2025
Sep 30, 2024
$2.26M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$2.36M
Aug 14, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($16.29M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($15.84M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($13.27M)
May 8, 2025
Q3
2025
Sep 30, 2024
($14.02M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($13.93M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($17.20M)
May 8, 2025
Q3
2024
Sep 30, 2023
($16.75M)
Nov 7, 2024
Q3
2023
Jun 30, 2023
($19.36M)
Nov 9, 2023
Q2
2024
Jun 30, 2023
($19.36M)
Aug 8, 2024
Q3
2023
Mar 31, 2023
($22.65M)
Nov 9, 2023
Q1
2024
Mar 31, 2023
($22.65M)
May 14, 2024
Q2
2023
Mar 31, 2023
($22.65M)
Aug 14, 2023
Q3
2023
Sep 30, 2022
($19.79M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($24.61M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($24.61M)
Aug 14, 2023
Q3
2023
Mar 31, 2022
($21.35M)
Nov 9, 2023
Q1
2023
Mar 31, 2022
($21.35M)
May 9, 2023
Q2
2023
Mar 31, 2022
($21.35M)
Aug 14, 2023
Q3
2022
Sep 30, 2021
($16.25M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($23.18M)
Aug 9, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.93M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($14.37M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($13.85M)
May 8, 2025
Q3
2025
Sep 30, 2024
($14.76M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($14.70M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($17.49M)
May 8, 2025
Q3
2024
Sep 30, 2023
($17.36M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($20.12M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($23.53M)
May 14, 2024
Q3
2023
Sep 30, 2022
($20.21M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($24.55M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($21.22M)
May 9, 2023
Q3
2022
Sep 30, 2021
($15.96M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($23.01M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($16.52M)
May 12, 2022
Q3
2021
Sep 30, 2020
($14.62M)
Dec 2, 2021